A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Feb 2019
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Epirubicin; Filgrastim; Paclitaxel; Pegfilgrastim
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms KEYNOTE-522
- Sponsors Merck Sharp & Dohme
- 25 Jan 2019 Planned End Date changed from 14 Mar 2025 to 30 Sep 2025.
- 25 Jan 2019 Planned primary completion date changed from 1 Nov 2018 to 30 Sep 2025.
- 28 Sep 2018 Status changed from recruiting to active, no longer recruiting.